Septerna (SEPN) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Septerna (SEPN) do?
Septerna Inc (SEPN) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Develops oral small-molecule medicines targeting G protein-coupled receptors for endocrine and metabolic diseases. Recreates cell membrane receptors outside cells to discover oral small-molecule medicines targeting GPCRs. It is worth $1.86B on the market and sold $96.28M over the last year.
- Market cap
- $1.86B
- P/E ratio
- None (reported a loss)
- Annual sales
- $96.28M
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 16, 2026
SEPN’s flags, in plain English
Each flag is a number from Septerna’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 16, 2026.
Stupid Cash
Can pay this year's bills 4.8 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Low debt
Low debt, only 5% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Wide Gross Margin
Gross margin of 98.3% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Burning Cash
Losing money, profit margin of -61.3%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.
1 more green flag and 2 more risk notes open with the free trial. Try it free for 7 days.
Questions about SEPN
How big is Septerna?
Septerna’s market cap is $1.86B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $96.28M: what customers paid the company over the last year, before any costs.
What is SEPN’s P/E ratio?
SEPN has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with SEPN?
The company generates no commercial product revenue and relies on existing cash reserves to fund drug development. That is one risk on Septerna’s card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Septerna’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. SEPN’s filings on SEC.gov. The Margin Monkey is research, not advice.
